無料レポート プレゼントキャンペーン 実施中 : メールサービスに新規登録いただいた方にご用意した無料レポートをご提供

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

高コレステロール血症:パイプライン製品の分析

Hypercholesterolemia - Pipeline Review, H1 2018

発行 Global Markets Direct 商品コード 192645
出版日 ページ情報 英文 203 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.67円で換算しております。
Back to Top
高コレステロール血症:パイプライン製品の分析 Hypercholesterolemia - Pipeline Review, H1 2018
出版日: 2018年05月31日 ページ情報: 英文 203 Pages
概要

高コレステロール血症は、血中コレステロールの高濃度が原因で生じます。特に心血管疾患につながる可能性があります。コレステロールは動脈に沈着し、血管の狭窄を引き起こし、血流を制限します。素因として、糖尿病、腎疾患、肥満などのさまざまな疾患が挙げられます。また、遺伝、特定の薬剤、座りがちな生活様式、喫煙、アルコール依存症、ストレス、高脂肪食なども挙げられます。症状は、動脈閉塞、下肢痛、胸痛、コレステロール沈着などが見られます。治療には、生活様式の変化、食生活の変化、禁煙、投薬などが含まれます。

当レポートでは、高コレステロール血症に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

目次

イントロダクション

高コレステロール血症の概要

治療薬の開発

治療薬の評価

治療薬開発に従事している企業

薬剤プロファイル

休止中のプロジェクト

開発が中止された製品

製品開発のマイルストーン

付録

図表

図表

List of Tables

  • Number of Products under Development for Hypercholesterolemia, H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Number of Products under Development by Universities/Institutes, H1 2018
  • Products under Development by Companies, H1 2018
  • Products under Development by Universities/Institutes, H1 2018
  • Number of Products by Stage and Target, H1 2018
  • Number of Products by Stage and Mechanism of Action, H1 2018
  • Number of Products by Stage and Route of Administration, H1 2018
  • Number of Products by Stage and Molecule Type, H1 2018
  • Hypercholesterolemia - Pipeline by AFFiRiS AG, H1 2018
  • Hypercholesterolemia - Pipeline by Akcea Therapeutics Inc, H1 2018
  • Hypercholesterolemia - Pipeline by AstraZeneca Plc, H1 2018
  • Hypercholesterolemia - Pipeline by BioLingus AG, H1 2018
  • Hypercholesterolemia - Pipeline by Catabasis Pharmaceuticals Inc, H1 2018
  • Hypercholesterolemia - Pipeline by Chong Kun Dang Pharmaceutical Corp, H1 2018
  • Hypercholesterolemia - Pipeline by CymaBay Therapeutics Inc, H1 2018
  • Hypercholesterolemia - Pipeline by Daewon Pharm Co Ltd, H1 2018
  • Hypercholesterolemia - Pipeline by Daewoong Co Ltd, H1 2018
  • Hypercholesterolemia - Pipeline by Dicerna Pharmaceuticals Inc, H1 2018
  • Hypercholesterolemia - Pipeline by Dybly AG, H1 2018
  • Hypercholesterolemia - Pipeline by Esperion Therapeutics Inc, H1 2018
  • Hypercholesterolemia - Pipeline by Gemphire Therapeutics Inc, H1 2018
  • Hypercholesterolemia - Pipeline by Golden Biotechnology Corp, H1 2018
  • Hypercholesterolemia - Pipeline by Immune Response BioPharma Inc, H1 2018
  • Hypercholesterolemia - Pipeline by Innovent Biologics Inc, H1 2018
  • Hypercholesterolemia - Pipeline by Kadmon Corp LLC, H1 2018
  • Hypercholesterolemia - Pipeline by Kyorin Pharmaceutical Co Ltd, H1 2018
  • Hypercholesterolemia - Pipeline by Leading BioSciences Inc, H1 2018
  • Hypercholesterolemia - Pipeline by LipimetiX Development Inc, H1 2018
  • Hypercholesterolemia - Pipeline by Madrigal Pharmaceuticals Inc, H1 2018
  • Hypercholesterolemia - Pipeline by Medlab Clinical Ltd, H1 2018
  • Hypercholesterolemia - Pipeline by Noxopharm Ltd, H1 2018
  • Hypercholesterolemia - Pipeline by Pfizer Inc, H1 2018
  • Hypercholesterolemia - Pipeline by Portola Pharmaceuticals Inc, H1 2018
  • Hypercholesterolemia - Pipeline by Progenra Inc, H1 2018
  • Hypercholesterolemia - Pipeline by Regeneron Pharmaceuticals Inc, H1 2018
  • Hypercholesterolemia - Pipeline by RegenxBio Inc, H1 2018
  • Hypercholesterolemia - Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, H1 2018
  • Hypercholesterolemia - Pipeline by Shenzhen HighTide Biopharmaceutical Ltd, H1 2018
  • Hypercholesterolemia - Pipeline by The Medicines Company, H1 2018
  • Hypercholesterolemia - Pipeline by Viking Therapeutics Inc, H1 2018
  • Hypercholesterolemia - Pipeline by Zhejiang Hisun Pharmaceutical Co Ltd, H1 2018
  • Hypercholesterolemia - Dormant Projects, H1 2018
  • Hypercholesterolemia - Discontinued Products, H1 2018

List of Figures

  • Number of Products under Development for Hypercholesterolemia, H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Number of Products under Development by Universities/Institutes, H1 2018
  • Number of Products by Top 10 Targets, H1 2018
  • Number of Products by Stage and Top 10 Targets, H1 2018
  • Number of Products by Top 10 Mechanism of Actions, H1 2018
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
  • Number of Products by Routes of Administration, H1 2018
  • Number of Products by Stage and Routes of Administration, H1 2018
  • Number of Products by Molecule Types, H1 2018
  • Number of Products by Stage and Molecule Types, H1 2018
目次
Product Code: GMDHC10471IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hypercholesterolemia - Pipeline Review, H1 2018, provides an overview of the Hypercholesterolemia (Metabolic Disorders) pipeline landscape.

Hypercholesterolemia is a condition characterized by very high levels of cholesterol in the blood. This leads in formation of sticky deposits (called plaque) along the artery walls. Plaque can completely block blood flow through an artery, causing heart attack or stroke. Two forms of the condition exist heterozygous familial hypercholesterolemia (HeFH) and homozygous familial hypercholesterolemia (HoFH). Risk factors include obese, family history, high blood pressure, smoking and diabetes. Treatment includes statins, bile acid sequestrants, fibric acid derivatives and cholesterol absorption inhibitors.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hypercholesterolemia - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Hypercholesterolemia (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hypercholesterolemia (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hypercholesterolemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, Preclinical, Discovery and Unknown stages are 1, 9, 13, 4, 1, 17, 5 and 3 respectively. Similarly, the Universities portfolio in Phase 0 and Preclinical stages comprises 1 and 6 molecules, respectively.

Hypercholesterolemia (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hypercholesterolemia (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Hypercholesterolemia (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hypercholesterolemia (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hypercholesterolemia (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hypercholesterolemia (Metabolic Disorders)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hypercholesterolemia (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hypercholesterolemia (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Hypercholesterolemia - Overview
  • Hypercholesterolemia - Therapeutics Development
  • Hypercholesterolemia - Therapeutics Assessment
  • Hypercholesterolemia - Companies Involved in Therapeutics Development
  • Hypercholesterolemia - Drug Profiles
  • Hypercholesterolemia - Dormant Projects
  • Hypercholesterolemia - Discontinued Products
  • Hypercholesterolemia - Product Development Milestones
  • Appendix
Back to Top